One retrospective study by Michel et al. (2020) retrieved from the literature search suggests that temporary off-label use of TPO-RAs for severe and/or refractory ITP during pregnancy benefits both mother and neonate, especially before delivery [58]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.